Ionis Pharmaceuticals Looks to Partners to Pay the Bills

Ionis Pharmaceuticals Looks to Partners to Pay the Bills

Source: 
Motley Fool
snippet: 

Ionis Pharmaceuticals (NASDAQ: IONS) continues to rack up royalties from its spinal muscular atrophy drug Spinraza while the rest of its extensive pipeline basically pays the rest of the biotech's bills.